Abstract
Tuberculosis (TB) is the second cause of death from a single infectious agent, the M. tuberculosis bacillus. Nearly two billion people are infected and about 8.7 million new cases and 1.4 million deaths were reported by the World Health Organization (WHO) in 2013. Despite the availability of effective treatment, the alarming emergence of multidrug resistant (MDR) strains (with 310.000 estimated cases in 2011 among notified patients with pulmonary TB), simultaneously resistant to the two most effective anti-TB drugs, isoniazid (INH) and rifampicin, has urged the need to develop new molecular scaffolds, either structurally original or based on old and active drugs. The aim of this review is to summarize the current status of different QSAR based strategies for the design of novel anti-TB drugs based upon the most active anti-TB agent known, INH. A case study puts in evidence that the judicious application of quantitative structure- activity relationships can be successfully used to rationally design new INH-based derivatives, active against INH-resistant strains harboring mutations in the most frequent resistance related target (katG), and therefore develop candidate-compounds against MDR-TB, thus revisiting the unique effectiveness of INH against TB.
Keywords: Multidrug-resistance, tuberculosis, isoniazid, QSAR based-design, new antitubercular drugs.
Current Pharmaceutical Design
Title:QSAR Based Design of New Antitubercular Compounds: Improved Isoniazid Derivatives Against Multidrug-Resistant TB
Volume: 20 Issue: 27
Author(s): Filomena Martins, Cristina Ventura, Susana Santos and Miguel Viveiros
Affiliation:
Keywords: Multidrug-resistance, tuberculosis, isoniazid, QSAR based-design, new antitubercular drugs.
Abstract: Tuberculosis (TB) is the second cause of death from a single infectious agent, the M. tuberculosis bacillus. Nearly two billion people are infected and about 8.7 million new cases and 1.4 million deaths were reported by the World Health Organization (WHO) in 2013. Despite the availability of effective treatment, the alarming emergence of multidrug resistant (MDR) strains (with 310.000 estimated cases in 2011 among notified patients with pulmonary TB), simultaneously resistant to the two most effective anti-TB drugs, isoniazid (INH) and rifampicin, has urged the need to develop new molecular scaffolds, either structurally original or based on old and active drugs. The aim of this review is to summarize the current status of different QSAR based strategies for the design of novel anti-TB drugs based upon the most active anti-TB agent known, INH. A case study puts in evidence that the judicious application of quantitative structure- activity relationships can be successfully used to rationally design new INH-based derivatives, active against INH-resistant strains harboring mutations in the most frequent resistance related target (katG), and therefore develop candidate-compounds against MDR-TB, thus revisiting the unique effectiveness of INH against TB.
Export Options
About this article
Cite this article as:
Martins Filomena, Ventura Cristina, Santos Susana and Viveiros Miguel, QSAR Based Design of New Antitubercular Compounds: Improved Isoniazid Derivatives Against Multidrug-Resistant TB, Current Pharmaceutical Design 2014; 20 (27) . https://dx.doi.org/10.2174/1381612819666131118164434
DOI https://dx.doi.org/10.2174/1381612819666131118164434 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
Call for Papers in Thematic Issues
"Tuberculosis Prevention, Diagnosis and Drug Discovery"
The Nobel Prize-winning discoveries of Mycobacterium tuberculosis and streptomycin have enabled an appropriate diagnosis and an effective treatment of tuberculosis (TB). Since then, many newer diagnosis methods and drugs have been saving millions of lives. Despite advances in the past, TB is still a leading cause of infectious disease mortality ...read more
Current Pharmaceutical challenges in the treatment and diagnosis of neurological dysfunctions
Neurological dysfunctions (MND, ALS, MS, PD, AD, HD, ALS, Autism, OCD etc..) present significant challenges in both diagnosis and treatment, often necessitating innovative approaches and therapeutic interventions. This thematic issue aims to explore the current pharmaceutical landscape surrounding neurological disorders, shedding light on the challenges faced by researchers, clinicians, and ...read more
Emerging and re-emerging diseases
Faced with a possible endemic situation of COVID-19, the world has experienced two important phenomena, the emergence of new infectious diseases and/or the resurgence of previously eradicated infectious diseases. Furthermore, the geographic distribution of such diseases has also undergone changes. This context, in turn, may have a strong relationship with ...read more
Melanoma and Non-Melanoma Skin Cancer Treatment: Standard of Care and Recent Advances
In this thematic issue, we aim to provide a standard of care of the diagnosis and treatment of melanoma and non-melanoma skin cancer. The editor will invite authors from different countries who will write review articles of melanoma and non-melanoma skin cancers. The Diagnosis, Staging, Surgical Treatment, Non-Surgical Treatment all ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Potential Crossreactivity of Human Immune Responses Against HCMV Glycoprotein B
Current Drug Discovery Technologies Host-Pathogen Interactions Made Transparent with the Zebrafish Model
Current Drug Targets Design, Synthesis and In Vitro Antimalarial Evaluation of New Quinolinylhydrazone Derivatives
Letters in Drug Design & Discovery Chaperone-like Activity of alpha-Crystallin and Other Small Heat Shock Proteins
Current Protein & Peptide Science Concise and Facile Synthesis of Novel Pyrano[2,3-d]pyrimidine-7- one/thione Derivatives as In Vitro Antimicrobial and Antitubercular Agents
Letters in Drug Design & Discovery Anti-Inflammatory and Analgesic Activity of Methanolic and Hydro- Alcoholic Extract of Myrsine africana L. Fruits
The Natural Products Journal Clinical Presentation, Treatment Outcome and Survival Among the HIV Infected Children with Culture Confirmed Tuberculosis
Current HIV Research Allergic Aspergillosis and the Antigens of Aspergillus fumigatus
Current Protein & Peptide Science Aminobisphosphonates as New Weapons for γ δ T Cell-Based Immunotherapy of Cancer
Current Medicinal Chemistry New Insights into Invasive Aspergillosis - from the Pathogen to the Disease
Current Pharmaceutical Design State of the Art of Nanobiotechnology Applications in Neglected Diseases
Current Nanoscience P2X Receptors and Inflammation
Current Medicinal Chemistry A Comprehensive Review on Phytochemistry and Pharmacological Effects of Stinging Nettle (Urtica dioica)
Current Traditional Medicine Macrophage Response to Mycobacterium tuberculosis During HIV Infection Relationships Between Macrophage Activation and Apoptosis.
Current Molecular Medicine An Overview of Phytotherapeutic Approaches for the Treatment of Tuberculosis
Mini-Reviews in Medicinal Chemistry Editorial (Thematic Issue: Searching a New Antibiotic Prototype: Snake Venoms)
Mini-Reviews in Organic Chemistry The Beneficial Role of Vitamin D in Human Immunodeficiency Virus Infection
Current HIV Research Update of QSAR & Docking Studies of the GSK-3 Inhibitors
Current Bioinformatics Molecular and Biochemical Features of the Mitochondrial Enzyme Ornithine Transcarbamylase: A Possible New Role as a Signaling Factor
Current Medicinal Chemistry The Apoptosis Mechanism of Epirubicin Combined with BCG on Human Bladder Cancer Cells
Anti-Cancer Agents in Medicinal Chemistry